SGS’s N.J. facility undergoes major expansion

Tuesday, September 25, 2012 03:44 PM

SGS Life Science Services has reopened its Fairfield, N.J. facility, having just completed a major renovation that involved doubling the size of facility, investing in new, increased laboratory space, expanded client accommodation and new equipment.

The expansion enlarges the size of the facility from 15,000 to 30,000 square feet, adding completely modernized and new GMP/GLP compliant laboratories and increases ICH Zone 1-4 storage capacities. Additionally, expanded accommodation for client audits and planning sessions were implemented as part of the design. Furthermore, SGS will invest significantly on new equipment to broaden its service offering in extractables and leachables, as well as heavy metals testing.

According to John Pirro, general manager of the Fairfield site, the facility has been designed to respond to the current and future needs of a changing bio/pharmaceutical environment. He said, "This investment will provide future capacity to service the growing needs of the bio/pharmaceutical market with expanded capabilities for stability and other project work."

Anne Hays, executive vice president, SGS, said, "With outsourcing becoming an integral part of large multinational pharmaceutical companies’ strategies, we want to assure our clients that we can accommodate both their routine and complex bio/pharmaceutical analytical outsourcing needs, integrating the latest developments in regulatory compliance."

Share:          
CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs